MAJOR ARTICLE
fi
Relative Ef cacy of AS03-Adjuvanted Pandemic
fl
In uenza A(H1N1) Vaccine in Children: Results
fi
of a Controlled, Randomized Ef cacy Trial
TerryNolan,1,2,aSumitaRoy-Ghanta,3,aMayMontellano,5LilyWeckx,8RolandoUlloa-Gutierrez,11EduardoLazcano-Ponce,12
AngkoolKerdpanich,16MarcoAurélioPalazziSafadi,9,10AurelioCruz-Valdez,12SandraLitao,6FongSengLim,18
AbielMascareñasdeLosSantos,13MiguelAngelRodriguezWeber,14Juan-CarlosTinoco,15MarcelaHernandez-deMezerville,11
IdisFaingezicht,11PensriKosuwon,17PioLopez,19CharissaBorja-Tabora,7PingLi,3SergeDurviaux,20LouisFries,4GaryDubin,3
ThomasBreuer,20BruceL.Innis,3andDavidW.Vaughn21
1MurdochChildren’sResearchInstituteand2MelbourneSchoolofPopulationandGlobalHealth,UniversityofMelbourne,Carlton,Australia;
3GlaxoSmithKlineVaccines,KingofPrussia,Pennsylvania;4Novavax,Rockville,Maryland;5DepartmentofPediatrics,MaryChilesGeneralHospital,
Manila,6DepartmentofPediatrics,DeLaSalleHealthSciencesInstitute,DasmariñasCity,and7DepartmentofHealth,ResearchInstituteforTropical
Medicine,Muntinlupa,Philippines;8PediatricInfectiousDiseases,DepartmentofPediatrics,UniversidadeFederaldeSãoPaulo,9Departmentof
Pediatrics,FaculdadedeCiênciasMédicasdaSantaCasadeSãoPaulo,and10AssociaçãoFundodeIncentivoàPesquisa,SãoPaulo,Brazil;11Instituto
CostarricensedeInvestigacionesClínicas,SanJosé,CostaRica;12NationalInstituteofPublicHealthofMexico,CuernavacaMorelos,13ServiciosMedicos
UniversidadAutonomadeNuevoLeon,Monterrey,14InstitutoNacionaldePediatríadeMexico,CiudadeMexico,and15HospitalGeneraldeDurango,
Durango,Mexico;16InfectiousDiseasesUnit,DepartmentofPediatrics,PhramongkutklaoHospital,Bangkok,and17DepartmentofPediatrics,Facultyof
Medicine,KhonKaenUniversity,KhonKaen,Thailand;18NationalHealthcareGroupPolyclinics,Singapore;19CentrodeEstudiosenInfectologiaPediatrica,
Cali,Colombia;and20GlaxoSmithKlineVaccines,Wavre,and21GlaxoSmithKlineVaccines,Rixensart,Belgium
Background. Thevaccineefficacy(VE)of1or2dosesofAS03-adjuvantedinfluenzaA(H1N1)vaccinerelative
tothatof2dosesofnonadjuvantedinfluenzaA(H1N1)vaccineinchildren6monthsto<10yearsofageinamul-
tinationalstudyconductedduring2010–2011.
Methods. A total of 6145 children were randomlyassigned at a ratio of 1:1:1 to receive 2 injections 21 days
apart of A/California/7/2009(H1N1)-AS03 vaccine at dose 1 and saline placebo at dose 2, 2 doses 21 days apart
ofA/California/7/2009(H1N1)-AS03vaccine(theAd2group),or2doses21daysapartofnonadjuvantedA/Cali-
fornia/7/2009(H1N1)vaccine(theNAd2group).Activesurveillanceforinfluenza-likeillnessescontinuedfromdays
14 to 385. Nose and throat samples obtained during influenza-like illnesses were tested for A/California/7/2009
(H1N1), using reverse-transcriptase polymerase chain reaction. Immunogenicity, reactogenicity, and safety were
assessed.
Results. Therewere23casesofconfirmed2009pandemicinfluenzaA(H1N1)(A[H1N1]pdm09)infectionfor
theprimaryrelativeVEanalysis.TheVEintheAd2grouprelativetothatintheNAd2groupwas76.8%(95%con-
fidenceinterval,18.5%–93.4%).ThebenefitoftheAS03adjuvantwasdemonstratedintermsofthegreaterimmu-
nogenicityobservedintheAd2group,comparedwiththeNAd2group.
Conclusion. The4–8-foldantigen-sparingadjuvantedpandemicinfluenzavaccinedemonstratedsuperiorand
clinicallyimportant prevention ofA(H1N1)pdm09infection,comparedwithnonadjuvanted vaccine, withnoob-
servedincreaseinmedicallyattendedorseriousadverseevents.Thesedatasupporttheuseofadjuvantedinfluenza
vaccinesduringinfluenzapandemics.
ClinicalTrialsRegistration. NCT01051661.
Keywords. H1N1;pandemicinfluenzavaccine;influenzavirus;children;efficacy.
Received11December2013;accepted3March2014;electronicallypublished DiseasesSocietyofAmerica.ThisisanOpenAccessarticledistributedundertheterms
20March2014. oftheCreativeCommonsAttribution-NonCommercial-NoDerivslicence(http://
aT.N.andS.R.-G.contributedequallytothiswork. creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial
Correspondence:TerryNolan,MD,PhD,MelbourneSchoolofPopulationand reproductionanddistributionofthework,inanymedium,providedtheoriginalwork
GlobalHealth,UniversityofMelbourne,Level5,207BouverieSt,Carlton,Victoria isnotalteredortransformedinanyway,andthattheworkisproperlycited.For
3010,Australia(t.nolan@unimelb.edu.au). commercialre-use,pleasecontactjournals.permissions@oup.com.
TheJournalofInfectiousDiseases 2014;210:545–57 DOI:10.1093/infdis/jiu173
©TheAuthor2014.PublishedbyOxfordUniversityPressonbehalfoftheInfectious
AS03-AdjuvantedInfluenzaA(H1N1)VaccineEfficacy (cid:129) JID 2014:210 (15August) (cid:129) 545
Children have high influenza attack rates and are key toviral that it could contribute no more than 75% to the total
transmission among households, daycare centers, and schools population.
[1,2].Duringthe 2009–2010 pandemic ofinfluenza A(H1N1)
Vaccines
(hereafter, A[H1N1]pdm09) infection, the highest attack rates
wereobservedinchildren<18yearsofage[3].Inactivatedinflu- Each dose of H1N1-AS03 vaccine contained 1.9µg of hemag-
enzavaccineshistoricallyhaveshownonlymoderateefficacyin glutinin (HA) mixed with AS03 Bin atotal delivery volume of
0.25mL.AS03 isanoil-in-wateremulsioncontainingsqualene
children,particularlyamongthose<2yearsofage[4],although B
improvedefficacyofanoil-in-water–adjuvanted(MF59)triva-
andDL-α-tocopherol(5.93mg)inanaqueousphase[7].
lent seasonal influenzavaccinewasrecentlyreportedinyoung Thenonadjuvantedvaccinecontained30µgofHAin1mL,
and the volume (ie, HA dose) administered varied with age:
children[5].Moreover,anantigen-sparingAS03-adjuvantedin-
activated pandemic influenzavaccine against A(H1N1)pdm09 children <3 years of age in the NAd2 group received two
0.25-mL doses (ie, 7.5µg of HA), and children 3 to <10 years
offered children superior immunogenicity relative to conven-
tional unadjuvanted formulations, with an acceptable safety of age received two 0.5-mL doses (ie, 15µg of HA). Placebo
profile [6]. Therefore, in a large cohort of children, we used was0.5mLofsaline.Singlelotsoftheadjuvantedantigen,non-
real-timepolymerasechainreaction(PCR)–basedconfirmation adjuvantedantigen,andadjuvantwereused.Vaccinesweread-
of A(H1N1)pdm09 infection to evaluate the efficacyof a split ministered into the deltoid (oranterior thigh, if the child was
<12monthsofage),usinganeedlelengthsuitableforintramus-
virionA/California/7/2009(H1N1)v-likeAS03-adjuvantedvac-
cularadministration.
cine(H1N1-AS03;Arepanrix[GlaxoSmithKlineVaccines])rel-
ativeto thatof anonadjuvanted H1N1 vaccine madewith the
StudyObjectives
samevirusstrainbutformulatedataconventionaldoseinpre-
Theprimaryobjectivewastoevaluatetheefficacyof2dosesof
venting A(H1N1)pdm09 infection. Antibody persistence was
H1N1-AS03relativetothatof2dosesofnonadjuvantedvaccine
monitored for either 6 months or 1 year after vaccination.
beginning14daysafterdose1andcontinuinguntilstudycon-
Ourobjectivewastoassesswhetherthevaccinecandidate’ssu-
clusiononday385.Noninferiorityintermsofrelativevaccine
perior immunogenicity translated into improved disease
efficacy(VE)wasconcludedifthelowerlimitofthe95%con-
prevention.
fidence interval (CI) for relative VE against real-time PCR–
confirmed A(H1N1)pdm09 infection (Ad2 vs NAd2) was
METHODS ≥33%. Superiority was concluded if the lower limit of the
95%CIforrelativeVEwas>0.
StudyDesignandSubjects Secondarystudyobjectives with predefined criteria (and no
This randomized, prospective phase 3 observer-blinded study
type 1 error adjustment) included (1) VE for Ad1 relative to
was conducted in 17 centers in Australia, Brazil, Colombia, thatofNAd2,usingthesamecriteriaspecifiedfortheprimary
Costa Rica, Mexico, the Philippines, Singapore, and Thailand
objective; (2) relative VE forany pneumonia, any pneumonia
between 15 February 2010 and 19 August 2011. The study in individuals within 6 weeks of real-time PCR–positive
was approved byan institutional review board at each partici- A(H1N1)pdm09infection,andanyinfluenza-likeillness(ILI);
pating center. Written informed consent was obtained from and(3)assessmentofspecificantibodytitersatday42.
parentsorguardiansofparticipatinghealthychildren6months
Theadjuvanteffectonimmunogenicitywasassessedbycom-
to <10 years (6 month to <10) of age before the children re-
paringA/California/7/09hemagglutination-inhibiting(HI)an-
ceivedthefirstvaccinedose.
tibody responses at day 42 in terms of geometric mean titer
(GMT) ratios and differences in seroconversion rate (SCR) by
Randomization
group. Adjuvant effect was demonstrated if the lower limit of
Participantswererandomlyassignedataratioof1:1:1to1of3
the 95% CI for GMT ratio was >1.0 and the lower limit of
treatment groupstoreceive2intramuscularinjections21days
the95%CIforthegroupdifferenceintheseroconversionrate
apart. Group Ad1 received H1N1-AS03 at dose 1 and placebo
was>0.
(saline) atdose 2;group Ad2received2dosesofH1N1-AS03; Reactogenicityandsafetyofthestudyvaccinesandantibody
groupNAd2received2dosesofnonadjuvantedA/California/7/
persistenceatdays182and385weresummarizeddescriptively
2009(H1N1) vaccine. The randomization procedure used a
aspartoftheevaluationofsecondaryobjectives.
minimization algorithm accounting forcenter, age stratum (6
to<36monthsor3to<10years),andpriorseasonalinfluenza EvaluationofInfluenzaOutcomes
vaccination status. These factors had equal weight in the Passivesurveillancebeganonday0andactivesurveillancevia
minimization algorithm; that is, a participant’s vaccine group telephonecontactsbeganforallsubjectsapproximately2weeks
allocation was based on the balance of the combination of all afterdose1andcontinuedevery1–2weeksuntilday385.Par-
the minimization factors. Each age stratum was capped such ents and legal guardians notified the investigator if the child
(cid:129) (cid:129)
546 JID 2014:210 (15August) Nolanetal
developed an ILI (defined as a temperature ≥38.0°C by any in youngerchildren (age, <6 years) versus olderchildren (age,
routeandatleast1ofthefollowing:neworworsening cough, ≥6 years). All otheradverse events (AEs) were recorded from
sore throat, nasal congestion, and/or rhinorrhea). Nasal and the first dose until day 42. Medically attended AEs, serious
throat swab specimens were collected within 7 days after AEs(SAEs),andpotentialimmune-mediateddiseaseswerere-
symptom onset. A 7-day symptom-free period was required cordeduntilday385.Allsolicitedinjectionsitereactionswere
betweenILI episodestoconsider thesubsequentepisodedis- consideredcausallyrelatedtovaccination.Potentiallycausalre-
tinctfromtheinitialepisode.DetectionofinfluenzaA(H1N1) lationshipsbetweenvaccinationandallotherAEswereassessed
pdm09,usingreal-timePCR(andofallinfluenzavirusstrains, bythesiteinvestigator.
usingmultiplexPCR),isdescribedintheSupplementaryMa-
terials.Onlyreal-timePCR–positivesamplesunderwentviral StatisticalMethods
culture[8]. Theanalysiswasperformedbyanexternallycontractedstatis-
ticalanalyst.Asecondstatisticianfromthesamecompanyper-
ImmunogenicityAssessment formedanindependentqualityvalidation.
Blood samples were collected before vaccination and 21 days
afterreceiptofdose2(ie,onday42)fromallsubjects.HIan- Vaccine Efficacy
tibody levels were measured in a random subset of approxi- Efficacywasassessedintheaccording-to-protocol(ATP)effica-
mately 60 children in each treatment group from each cycohort,whichincludedallevaluablesubjectswhoreceived2
participating country. The HI assay used chicken erythrocytes doses, who were successfully contacted at least once after the
[9–11],and the lowest dilution tested was 1:10. The titration firstvaccination,andwhocompliedwithprotocol-definedpro-
end point wasthe highest dilution step that showed complete cedures.TherelativeVEwascalculatedas1−relativerisk(RR),
(ie,100%)inhibitionofhemagglutination.Afurtherbloodsam- wheretheRRisdefinedastheriskofreal-timePCR–confirmed
plewascollectedateitherday182orday385fromconsenting cases among subjects receiving H1N1-AS03 versusthe riskof
subjects. real-time PCR–confirmed cases among subjects receiving
NAd2.RRwasestimatedviaaCoxproportionalhazardregres-
SafetyandReactogenicityAssessment sion model (time to first event), with vaccine group as afixed
Injection site and systemic symptoms were recorded on diary variable,and wasadjustedbycovariatesofage,seasonalinflu-
cards for 7 days after each dose. Solicited symptoms were enzavaccine history, and country. Subjects meeting censoring
basedontheabilitytoreportbyageandwerethereforedifferent criteria (ie, receipt of protocol-forbidden vaccines or
Table1. NumberofCasesofConfirmedA(H1N1)Disease,Pneumonia,andInfluenza-LikeIllnessDuringtheStudyPeriod(Days14to385)
Age,StudyGroup
AllSubjects 6moto<3y 3yto<10y
Event Ad2 Ad1 NAd2 Ad2 Ad1 NAd2 Ad2 Ad1 NAd2
ATPefficacycohortfollowedup,subjects,no.a 1903 1913 1897 569 566 561 1334 1347 1336
Influenza-likeillness 1390 1321 1330 616 626 609 774 695 721
Pneumonia 17 13 18 9 11 12 8 2 6
Real-timePCR–confirmedinfluenzab 3 6 11 1 0 2 2 6 9
Culture-confirmedinfluenza 2 5 6 0 0 0 2 5 6
Real-timePCR–confirmedinfluenzawithpneumonia 0 0 0 0 0 0 0 0 0
Totalvaccinatedcohortfollowedup,subjects,no. 2048 2048 2049 610 612 613 1438 1436 1436
Influenza-likeillness 1491 1441 1433 657 685 659 834 756 774
Pneumonia 18 14 22 9 11 15 9 3 7
Real-timePCR–confirmedinfluenzab 3 7 15 1 1 4 2 6 11
Culture-confirmedinfluenza 2 6 9 0 1 2 2 5 7
Real-timePCR–confirmedinfluenzawithpneumonia 0 0 0 0 0 0 0 0 0
Dataareno.ofcases,unlessotherwiseindicated.
Abbreviations:Ad1,A/California/7/2009(H1N1)-AS03vaccineatdose1andsalineplaceboatdose2;Ad2,2dosesofA/California/7/2009(H1N1)-AS03vaccine;ATP,
accordingtoprotocol;NAd2,2dosesofnonadjuvantedA/California/7/2009(H1N1)vaccine;PCR,polymerasechainreaction.
aSubjectswithprotocoldeviationorviolationwereexcludedfromtheATPcohort.However,subjectswhoreceivedconcomitantmedicationorvaccinewere
includedinthetime-to-eventefficacyanalysisandwerecensoredatthetimewhentheconcomitantmedicationorvaccinewasreceived.
bThreeadditionalcasesoccurredbeforeday14.
AS03-AdjuvantedInfluenzaA(H1N1)VaccineEfficacy (cid:129) JID 2014:210 (15August) (cid:129) 547
medication or receipt of nonprotocol vaccines containing A/ <1:10) with a postvaccination titerof ≥1:40 or the percentage
California/7/09-likeH1N1antigen)wereincludedintheanal- of initiallyseropositive vaccinees (titer, ≥1:10) with a ≥4-fold
ysisuntilthedateofcensoringorwereexcludedifthecensoring increaseinthepostvaccinationtiter;seroprotectionrate,defined
criteriaweremetbeforethediseaseendpointoccurred.Therel- asthe percentage of subjects with titers of ≥1:40 [12,13]; and
ativeVE(with95%CI)wascalculatedforthe14–385-day(pri- seroconversionfactor,definedastheratioofthepostvaccination
maryendpoint)and0–385-daysurveillanceperiods.Secondary titertotheprevaccinationtiter.
analyses were done on the total vaccinated cohort, which in-
cludedallchildrenwhoreceivedatleast1vaccinedose. Reactogenicity End Points
During study preparation the future behavior of the pan- Reactogenicitydataweresummarizedbyvaccinegroupandage
demic was uncertain, but we projected a substantive third stratum (from 6monthsto <6 years and from 6to <10years)
wave in 2010. On the basis of 1800 evaluable subjects per because a different AE intensityscalewas used forchildren of
group,anassumedattackrateof20%amongunvaccinatedsub- differentages.
jects,andanassumedVEfornonadjuvantedH1N1vaccineof
40%, if 360 real-time PCR–confirmed influenza cases were RESULTS
identified during the surveillance period, a lower limit of
≥33%forthe95%CIfortherelativeVEcouldbedemonstrated StudySubjects
with >99.9% power, if the VE in the H1N1-AS03 group was Each study center contributed between 105 (1.7%) and 886
assumed to be 60% relative to that of a notional placebo. (14.4%) of the total 6145 enrolled and vaccinated subjects. Of
Type1erroradjustmentwasnotmadeforsecondaryobjective these, 5900 (96%) completed the study to day 42, and 5851
evaluations. (95%) completed the study to day 385. Two children in the
Ad1 group withdrew before day 42 because of an AE or SAE:
Immunogenicity End Points 1 child died of asthma and pneumonia 20 days after dose 1,
Thefollowingparameterswerecalculated(with95%CIs)based and1childhadanonseriousupperrespiratorytractinfection.
on A/California/7/09 HI titers: GMT; seroconversion rate, de- TwochildreninAd2werewithdrawnbeforeday385becauseof
fined asthe percentage of initiallyseronegative subjects (titer, SAEs: 1 child drowned, and 1 died from an intestinal
Figure1. Kaplan–Meiertime-to-eventcurveforreal-timepolymerasechainreaction–confirmed2009pandemicinfluenzaA(H1N1)infectionreportedfrom
14daysaftervaccinationthroughtheendofinfluenza-likeillnesssurveillance.aDataareforthetime-to-eventanalysisoftheaccording-to-protocolcohort;
bDatafor1subjectwerecensoredbeforetheeventandarethusnotincluded.Abbreviations:Ad1,A/California/7/2009(H1N1)-AS03vaccineatdose1and
salineplaceboatdose2;Ad2,2dosesofA/California/7/2009(H1N1)-AS03vaccine;NAd2,2dosesofnonadjuvantedA/California/7/2009(H1N1)vaccine.
(cid:129) (cid:129)
548 JID 2014:210 (15August) Nolanetal
Table2. Time-to-EventAnalysisoftheRelativeVaccineEfficacy(VE)forPrimaryandSecondaryOutcomesintheAccording-to-ProtocolEfficacyCohort
RelativeVE,a%(95%CI),byAgeandStudyGroups
AllSubjects 6to<36mo 3to<10y
Outcome,SurveillancePeriod Ad2vsNAd2 Ad1vsNAd2 Ad2vsNAd2 Ad1vsNAd2 Ad2vsNAd2 Ad1vsNAd2
Real-timePCR–confirmedinfluenza
Days14–385 76.8(18.5to93.4)a,b,c 46.4(−34.4to78.6) 75.5(−119.2to97.3) 74.6(−127.3to97.2) 77.5(−4.0to95.2)a 33.1(−88.1to76.2)
Days0–385 69.2(5.4to89.9)a,b 31.0(−61.4to70.5) 75.5(−119.2to97.3) 49.4(−176.1to90.7) 66.4(−24.0to90.9)a 21.9(−109.9to70.9)
Culture-confirmedinfluenza
Days14–385 74.9(−18.2to94.7)a 25.5(−114.9to74.1) 100 48.8(−465.0to95.4) 66.2(−67.3to93.2) 16.4(−173.9to74.5)
Days0–385 62.5(−41.3to90.1) 13.0(−140.0to68.5) 100 −1.7(−622.2to85.7) 49.7(−101.3to87.4) 16.4(−173.9to74.5)
Anypneumonia
Days14–385 21.0(−52.5to59.1) 34.9(−31.0to67.6) 44.3(−32.9to76.6) 20.6(−75.0to64.0) −33.6(−285.2to53.6) 67.2(−62.6to93.4)
Days0–385 28.4(−36.4to62.4) 31.5(−32.2to64.4) 51.4(−13.5to79.2) 24.0(−60.7to64.1) −33.6(−285.2to53.6) 50.7(−97.0to87.7)
Influenza-likeillness
Days14–385 −2.5(−12.6to6.8) 1.9(−8.0to10.9) −0.3(−16.5to13.7) −5.1(−22.2to9.6) −3.7(−17.2to8.3) 6.4(−5.9to17.4)
Days0–385 −4.5(−14.7to4.7) −0.3(−10.2to8.7) −4.8(−21.3to9.5) −7.3(−24.3to7.5) −4.2(−17.5to7.6) 4.2(−8.2to15.1)
FindingswereobtainedbyaCoxregressionmodelwithadjustmentforcovariate(s)ofcountry,age,andseasonalinfluenzavaccinehistory.
Abbreviations:Ad1,onedoseofA/California/7/2009(H1N1)-AS03vaccineatdose1andsalineplaceboatdose2;Ad2,2dosesofA/California/7/2009(H1N1)-AS03vaccine;CI,confidenceinterval;NAd2,2dosesof
nonadjuvantedA/California/7/2009(H1N1)vaccine;PCR,polymerasechainreaction;VE,Vaccineefficacy.
aNoninferioritycriteriamet.
bSuperioritycriteriamet.
cPrimaryendpoint:noninferioritywasconcludedifthelowerlimitofthe95%CIfortherelativeVEinsubjectswithreal-timePCR–confirmedA(H1N1)influenza(Ad2dividedbyNAd2group)was≥33%.Superioritywas
achievedifthelowerlimitofthe95%CIfortherelativeVEinsubjectswithreal-timePCR–confirmedA(H1N1)influenza(Ad2dividedbyNAd2group)was>0.Forallothercomparisons,thetype1errorwasnotcontrolled.
AS03-AdjuvantedInfluenzaA(H1N1)VaccineEfficacy
(cid:129)
JID
2014:210
(15August)
(cid:129)
549
Table3. HumoralImmuneResponsetoA/California/7/2009(H1N1)v-likeStrainAfterVaccinationinAllSubjectsandAcrossAgeStratainAccording-to-ProtocolCohortsEvaluatedfor
ImmunogenicityandAntibodyPersistence
SCRc SPRh
Age,StudyGroup TimePointa No.b No.d %e(95%CIf) SCFg(95%CIf) No.b No.d %e(95%CIf) GMT(95%CIf)
Allages
Ad2 Before . . . . .. . . . . . . 395 127 32.2(27.6,37.0) 14.1(12.3,16.3)
Day42 395 394 99.7(98.6,100) 110.9(96.4,127.6) 400 400 100(99.1,100) 1562.3(1466.9,1663.8)
Day182 110 104 94.5(88.5,98.0) 21.8(17.8,26.7) 564 558 98.9(97.7,99.6) 253.4(231.7,277.2)
Day365 95 88 92.6(85.4,97.0) 21.1(16.9,26.4) 522 508 97.3(95.5,98.5) 211.9(193.8,231.7)
Ad1 Before . . . . .. . . . . . . 381 100 26.2(21.9,31.0) 12.3(10.7,14.1)
Day42 381 373 97.9(95.9,99.1) 22.1(20.4,23.9) 388 383 98.7(97.0,99.6) 266.5(235.5,301.5)
Day182 126 87 69.0(60.2,77.0) 7.1(6.2,8.2) 566 408 72.1(68.2,75.7) 97.3(86.4,109.6)
Day365 83 52 62.7(51.3,73.0) 7.6(6.1,9.4) 502 394 78.5(74.6,82.0) 106.4(94.7,119.6)
NAd2 Before . . . . .. . . . . . . 381 108 28.3(23.9,33.2) 13.3(11.5,15.4)
Day42 381 342 89.8(86.3,92.6) 20.5(18.3,23.1) 387 359 92.8(89.7,95.1) 271.3(235.4,312.7)
Day182 110 66 60.0(50.2,69.2) 6.2(5.1,7.6) 563 454 80.6(77.1,83.8) 116.9(104.1,131.3)
Day365 89 36 40.4(30.2,51.4) 4.4(3.6,5.5) 502 341 67.9(63.6,72.0) 78.4(68.9,89.2)
6moto<3y
Ad2 Before . . . . .. . . . . . . 229 61 26.6(21.0,32.9) 12.4(10.2,15.1)
Day42 229 228 99.6(97.6,100) 140.8(116.6,170.0) 233 233 100(98.4,100) 1738.9(1598.7,1891.4)
Day182 70 66 94.3(86.0,98.4) 24.0(18.5,31.1) 186 184 98.9(96.2,99.9) 287.2(246.8,334.3)
Day365 62 58 93.5(84.3,98.2) 26.6(20.0,35.3) 173 169 97.7(94.2,99.4) 265.6(228.9,308.2)
Ad1 Before . . . . .. . . . . . . 228 55 24.1(18.7,30.2) 11.2(9.3,13.4)
Day42 228 224 98.2(95.6,99.5) 23.4(21.2,25.7) 232 229 98.7(96.3,99.7) 258.0(219.9,302.8)
Day182 75 54 72.0(60.4,81.8) 8.0(6.8,9.3) 177 120 67.8(60.4,74.6) 76.5(62.0,94.5)
Day365 51 35 68.6(54.1,80.9) 8.5(6.5,11.0) 163 128 78.5(71.4,84.6) 112.6(91.3,138.8)
NAd2 Before . . . . .. . . . . . . 220 55 25.0(19.4,31.3) 12.3(10.0,15.1)
Day42 220 187 85.0(79.6,89.4) 15.6(13.5,18.0) 223 199 89.2(84.4,93.0) 188.9(156.1,228.5)
Day182 61 32 52.5(39.3,65.4) 4.8(3.7,6.3) 184 117 63.6(56.2,70.5) 74.9(59.1,95.1)
Day365 55 18 32.7(20.7,46.7) 3.7(2.8,4.7) 158 82 51.9(43.8,59.9) 54.9(42.2,71.5)
3yto<10y
Ad2 Before . . . . .. . . . . . . 166 66 39.8(32.3,47.6 16.9(13.8,20.8)
Day42 166 166 100(97.8,100) 79.9(65.3,97.6) 167 167 100(97.8,100) 1345.4(1228.3,1473.6)
Day182 40 38 95.0(83.1,99.4) 18.4(13.1,25.8) 378 374 98.9(97.3,99.7) 238.3(213.3,266.2)
Day365 33 30 90.9(75.7,98.1) 13.7(9.9,19.0) 349 339 97.1(94.8,98.6) 189.4(169.6,211.6)
Ad1 Before . . . . .. . . . . . . 153 45 29.4(22.3,37.3) 14.2(11.5,17.5)
Day42 153 149 97.4(93.4,99.3) 20.3(17.7,23.3) 156 154 98.7(95.4,99.8) 279.5(229.6,340.31)
Day182 51 33 64.7(50.1,77.6) 6.1(4.7,7.9) 389 288 74.0(69.4,78.3) 76.5(62.0,94.5)
Day365 32 17 53.1(34.7,70.9) 339 266 78.5(73.7,82.7) 103.6(89.9,119.3)
550
(cid:129)
JID
2014:210
(15August)
(cid:129)
Nolanetal
obstructionassociatedwithparasiticgastroenteritisandaspira-
tion pneumonia (95 days after dose 2). No event leading to
withdrawalwasconsidered related tovaccination.Subject flow
throughthestudyand reasonsforwithdrawalandelimination
fromATPcohortsaregiveninSupplementaryFigure1.
The mean age (±SD) of all children at enrollment was
4.3±2.64 years (range, 0.5–9 years); 49.8% (3058/6145) were
female.Thestudygroupsineachanalysiscohortwerecompa-
rable in terms of demographic characteristics (Supplementary
Table1).
VaccineEfficacy
There were 3731 nasopharyngeal swab specimens collected
from4653ILIepisodes(81%).MultiplexPCR–confirmedinflu-
enzavirusinfection(anystrainfromdays14to385)occurredin
9.7%(95%CI,8.4%–11.1%)ofchildrenintheAd2group,8.4%
(95% CI, 7.2%–9.8%) in the Ad1 group, and 9.3% (95% CI,
8.1%–10.7%)intheNAd2group.
During the entire study follow-up period, 28 children had
real-timePCR–confirmedA(H1N1)pdm09infection(Table1):
11wereinthePhilippines,7wereinThailand,5wereinAus-
tralia,3wereinMexico,and1eachwasinSingaporeandCosta
Rica. Three children developed influenza before day 14. One
child (in the NAd2 group) received the second vaccination 4
days after the protocol-specified visit window. One subject (in
the NAd2 group) was censored upon receiving seasonal triva-
lent vaccine 8monthsafter dose 1and 3monthsbeforeonset
ofA(H1N1)pdm09disease.Therefore,among5803childrenin-
cludedinATPtime-to-eventefficacyanalysis(days14–385),23
had real-time PCR-confirmed A(H1N1)pdm09 infection, giv-
ing an attack rate in each group of 0.15% (in the Ad2 group),
0.34% (in the Ad1 group), and 0.68% (in the NAd2 group) in
theATPcohort (Figure1).
The efficacy of Ad2 over NAd2 for prevention of real-time
PCR-confirmedA(H1N1)pdm09infectionfromdays14to385
was 76.8% (95% CI, 18.5%–93.4%). Both noninferiority and
superiorityofAd2versusNAd2werethusdemonstratedaccord-
ingtotheprespecifiedstatisticalcriteria(Table2).TherelativeVE
withoutadjustmentforcovariatesofage,seasonalinfluenzavac-
cinehistory,andcountrywas77.1%(95%CI,19.6%–93.5%).
Efficacy, noninferiority, and superiorityof the 2-dose adju-
vantedregimenwereconfirmedintheanalysisofthetotalvac-
cinated cohort: the efficacy estimate for Ad2 over NAd2 was
78.5%(95%CI,25.1%–93.8%;days14–385).
Secondary analyses showed that Ad2 was noninferior to
NAd2 for efficacy in preventing culture-confirmed influenza
(days 14–385) and in preventing real-time PCR–confirmed
A(H1N1)pdm09infectioninthe subgroupaged3to<10years
(Table1).Noninferioritywasalsoobservedfortheseendpoints
inthetotalvaccinatedcohortanalysis(datanotshown).
ThenoninferioritycriteriawerenotmetforAd1versusNAd2
fortheATPpopulationoratanyanalysisinterval(days14–385or
.deunitnoc
3elbaT
hRPS
cRCS
)fIC%59(TMG
)fIC%59(e%
d.oN
b.oN
)fIC%59(gFCS
)fIC%59(e%
d.oN
b.oN
atnioPemiT
puorGydutS,egA
)1.81,0.21(8.41
)8.04,7.52(9.23
35
161
.
.
.
.
.
.
..
.
.
.
.
erofeB
2dAN
)0.735,0.763(0.444
)3.99,9.39(6.79
061
461
)7.53,1.52(9.92
)6.89,1.29(3.69
551
161
24yaD
)0.461,3.821(1.541
)9.19,3.58(9.88
733
973
)4.11,4.6(5.8
)7.18,6.45(4.96
43
94
281yaD
)3.601,2.08(3.29
)8.97,4.07(3.57
952
443
)7.8,2.4(1.6
)2.07,1.53(9.25
81
43
563yaD
2,2dAN;retitnaemcirtemoeg,TMG;lavretniecnedifnoc,IC;eniccav30SA-)1N1H(9002/7/ainrofilaC/Afosesod2,2dA;2esodtaobecalpenilasdna1esodtaeniccav30SA-)1N1H(9002/7/ainrofilaC/A,1dA:snoitaiverbbA
.rotcafnoisrevnocores,FCS;etarnoitcetorpores,RPS;etarnoisrevnocores,RCS;eniccav)1N1H(9002/7/ainrofilaC/Adetnavujdanonfosesod
.2esodfotpiecerretfasyad563dna,281,24syaddnanoitaniccaverofeBa
.stluserelbaliavahtiwstcejbusfo.oneraataDb
noitaniccaverpehtsemit4≥foretitnoitaniccavtsopasadna)01:1<foretitydobitnagnitibihni-ninitulggamehahtiwesoht,ei(evitagenoresyllaitinierewohwstcejbusrofnoitaniccavretfa04:1≥retitydobitnanasadenifeDc
.evitisoporesyllaitinierewohwstcejbusrofretit
.elbaliavastlusernoitaniccavtsopdna-erphtiwstcejbusfo.oneraataDd
.tniopdnedetacidniehtdehcaerohwstcejbusfoegatnecreperaataDe
lanicideMrofeettimmoC.%07>saw04:1≥foretitahtiwegatnecrepehtrofIC%59ehtfotimilrewolehtdna,%04>sawRCSrofIC%59ehtfotimilrewoleht;dellifluferewairetirchcraeseRdnanoitaulavEscigoloiBrofretneCf
.5.2>sawFCSrofetamitsetniopehtdna,%07>saw04:1≥foretitahtiwegatnecrepehtrofetamitsetniopnoitaniccavtsopeht,%04>sawRCSrofetamitsetniopeht;dellifluferewairetircesUnamuHrofstcudorP
.])TMGnoitaniccaverp/TMGnoitaniccavtsop(
gol[naemsadetaluclac,oitarnaemcirtemoegehtsadenifeDg
01
.noitaniccavretfa04:1≥foretitydobitnanahtiwegatnecrepehtsadenifeDh
AS03-AdjuvantedInfluenzaA(H1N1)VaccineEfficacy (cid:129) JID 2014:210 (15August) (cid:129) 551
andCommitteeforMedicinalProductsforHumanUsecriteria
(definedinTable3)werefulfilledbyalltreatmentgroups(over-
allandbyeachagestratum)atday42.
Adjuvanteffect (Ad2vsNAd2groups)wasdemonstratedin
termsofseroconversionrate(lowerlimitofthe95%CIforthe
difference between groups, 7.2%)and GMTratios (lower limit
for95%CI,4.9).Adjuvanteffectwasalsodemonstratedinboth
agestrata(lowerlimitfor95%CIforthedifferenceinserocon-
version rate between groups, 10.3% forages 6 to <36 months
and 1.4% for ages 3 to <10 years; lower limit for the 95% CI
of the GMT ratio, 7.7 for ages 6 to <36 months and 2.4 for
ages3to<10years;Figure2).
Adjuvant effect was also observed for Ad1 versus NAd2
in terms of seroconversion rate overall (lower limit of the
95% CI for the difference between groups, 0.9%) but not
for GMT ratios. Adjuvant effect was observed for children
aged 6 to <36 months in terms of seroconversion rate (lower
limit of the 95% CI for the difference between groups, 8.6%)
and GMT ratios (lower limit for the 95% CI on the GMT
ratio,1.3).
Atday385,theseroprotectionratewas97.3%forAd2,78.5%
forAd1,and67.9%forNAd2(Table3).HIGMTswerehighest
intheAd2groupatallpostvaccinationtimepoints(Table3).
ReactogenicityandSafety
Painattheinjectionsitewasthemostfrequentlyreportedsymp-
tominallgroupsaftereach dose(Figure 3) and wasmore fre-
quent for Ad2 than NAd2. Grade 3 injection site reactions
werereportedbynomorethan4.3%ofchildrenaftereitherdose.
Thepercentageofchildrenineachagestratumreportingsys-
temicsolicitedsymptomswassimilaramongtreatmentgroups
and after doses1and 2(Figure3),with theexception of fever
(oraloraxillarytemperature,≥38.0°C)intheAd2group,which
increased from 10.2% (95% CI, 8.6%–11.9%) after dose 1 to
19.0% (95% CI, 16.9%–21.2%) after dose 2 in subjects aged 6
monthsto<6years(anincreasewasobservedinthesubgroups
Figure2. Reversecumulativecurvesforhemagglutination-inhibiting(HI)
aged6to<36monthsand3to<6years;SupplementaryTable2)
antibody(Ab)titersatday42,day182,andday385inallchildren(ie,the
and from 4.8% (95% CI, 3.3%–6.6%) to 8.7% (95% CI, 6.7%–
according-to-protocolimmunogenicitycohort).Abbreviations:Ad1,A/Cali-
fornia/7/2009(H1N1)-AS03vaccineatdose1andsalineplaceboatdose2; 11.1%), respectively, in subjects aged 6 to <10 years. In the
Ad2,2dosesofA/California/7/2009(H1N1)-AS03vaccine;HA,hemagglu- Ad2 group, grade 3 fever (oral or axillary temperature of
tinin;NAd2,2dosesofnonadjuvantedA/California/7/2009(H1N1)vaccine. ≥39.0°C) was reported for 1.9% (95% CI, 1.2%–2.8%) of chil-
dren aged 6 months to <6 years after dose 1 and for 3.1%
(95%CI,2.2%–4.2%)afterdose2.Fever(definedasatemper-
0–385) but were met for real-time PCR–confirmed A(H1N1) atureof>40.0°C)wasonlyreportedafterdose1:2episodesoc-
pdm09 infection (relative VE, 50.1% [95% CI, −23.5% to curredinchildrenintheAd2group,and3episodesoccurredin
79.9%])inthetotalvaccinatedcohort (days14–385). eachoftheothergroups(SupplementaryTable2).
Therewere15childrenwhoexperiencedfebrileconvulsions
Immunogenicity through day 385: 4 were in the Ad2 group, 6 were in the Ad1
TheATPimmunogenicitysubsetincluded1175childrenatday group,and5wereintheNAd2group.Sevenfebrileconvulsions
42,1693atday182,and1526atday385.Atday42,thesero- werereportedasSAEs(Table4).Noneoccurredwithin42days
protectionratewas100%forAd2,98.7%forAd1,and92.8%for aftervaccination,andnonewereconsideredvaccinerelated.One
NAd2(Table3).CenterforBiologicsEvaluationandResearch so-calledconvulsion(feverwasabsent)wasreportedthroughday
(cid:129) (cid:129)
552 JID 2014:210 (15August) Nolanetal
Figure3. Percentageofsubjectsreportinginjectionsitereactionsandgeneralsymptoms0–6daysaftereachvaccinedose.Verticallinesindicate95%
confidenceintervals.Inchildren<6yearsofage,grade3severitywasdefinedaspain(ie,cryingwhenlimbismovedorwithspontaneoussensationofpain),
rednessorswellinginanarea>100mmindiameter,fever(ie,anoraloraxillarytemperatureof≥39.0°C),irritability(ie,cryingthatcannotbecomfortedor
thatpreventsnormalactivity),drowsiness(ie,preventionofnormalactivity),andlossofappetite(noteatingatall).Inchildren6to<10yearsofage,grade3
severitywasdefinedaspainthatpreventsnormalactivity,rednessorswellinginanarea>100mmindiameter,fever(ie,anoral/axillarytemperatureof
≥39.0°C),and,forallothersymptoms,preventionofnormalactivity.
42aftervaccination(onset,7daysaftervaccinationinasubject group), who drowned; 1 involved a 20-month-old child (in
from the Ad2 group who had preexisting epilepsy). The event theAd2group),whodiedfromintestinalobstruction,parasitic
lasted6daysandwasnotconsideredtobevaccinerelated. gastroenteritis,andaspirationpneumonia;and1involveda6-
PercentagesofchildrenwithanyAEwithin42daysofvacci- month-oldchild(intheAd1group),whohadahistoryofpneu-
nationrequiringamedicallyattendedvisitweresimilaramong monia and asthma and died 20 days after vaccination from
groups(23.4%fortheAd2group,22.9%fortheAd1group,and community-acquired pneumonia and asthma (real-time PCR
22.8%fortheNAd2group;Table4). negative).Noautopsywasdone.
Duringthe42-dayfollow-upperiod,0.5%ofsubjectsinthe Duringthestudyperiod,1potentialimmune-mediateddis-
Ad2 group, 0.9% in the Ad1 group, and 1.2% in the NAd2 easewasreportedfortheAd2group(0.05%ofsubjects),and3
groupreportedatleast1grade3AE.Noneofthegrade3symp- and4fortheAd1(0.15%)andNAd2(0.2%)groups,respectively
tomsreportedintheAd2groupwereconsideredtobevaccine (Table4).
related.Onecaseofgrade 3headacheintheAd1group and1
caseeachofgrade 3vomiting andgastroenteritisintheNAd2 DISCUSSION
groupwereassessedaspotentiallyvaccinerelated.
Percentagesofchildrenexperiencingatleast1SAEfromdays This isthe first prospective efficacystudy commencing during
0 to385 were 3.7% inthe Ad2 group, 3.2% in theAd1 group, an influenza pandemic and the first to assess an AS03-
and3.3%intheNAd2group.The10mostfrequentlyreported adjuvantedinactivatedinfluenzavaccineinchildren.Wefound
SAEsweresimilaracrossgroups(Table4).OneSAE(whichin- aclinicallyimportantandstatisticallysignificantimprovement
volvedasubjectintheAd1group,whorequiredanemergency intheefficacyofAS03-adjuvantedvaccine,comparedwitheffi-
department visit for gastroenteritis, with onset on the dayof cacy of the nonadjuvanted influenza vaccine. Moreover, im-
dose 2) was considered to be vaccine related. There were 3 proved efficacy was shown using one-fourth to one-eighth of
fatal events (all in the Philippines), and nonewere considered the standard dose of HA, and noninferiority was shown fora
vaccine related: 1 involved a 10-year-old child (in the Ad2 singledoseofadjuvantedvaccine(one-eighthtoone-sixteenth
AS03-AdjuvantedInfluenzaA(H1N1)VaccineEfficacy (cid:129) JID 2014:210 (15August) (cid:129) 553
Table4. SafetyOutcomesandCommonAdverseEventPresentationsFromDays0to385AfterVaccinationintheTotalVaccinatedCohort
Ad2Group(n=2048) Ad1Group(n=2048) NAd2Group(n=2049)
Outcome No. %(95%CI) No. %(95%CI) No. %(95%CI)
Days0–42follow-upperiod
AnyunsolicitedAE 913 44.6(42.4,46.8) 904 44.1(42.0,46.3) 895 43.7(41.5,45.9)
AnyunsolicitedAEwitha 479 23.4(21.6,25.3) 468 22.9(21.0,24.7) 467 22.8(21.0,24.7)
medicallyattendedvisit
AnyrelatedAE 60 2.9(2.2,3.8) 57 2.8(2.1,3.6) 52 2.5(1.9,3.3)
Anygrade3AE 11 0.5(0.3,1.0) 18 0.9(0.5,1.4) 24 1.2(0.8,1.7)
Anyrelatedgrade3AE 0 . .. 1(vomiting) <0.001 2(headache) <0.001(vomiting,
gastroenteritis)
AnySAE 8 0.4(0.2,.8) 8 0.4(0.2,.8) 9 0.4(0.2,.8)
AnyrelatedSAE 0 1(gastroenteritis) 0
Days0–385follow-upperiod
AnyunsolicitedAE 1189 58.1(55.9,60.2) 1173 57.3(55.1,59.4) 1190 58.1(55.9,60.2)
AnySAE 76 3.7(2.9,4.6) 66 3.2(2.5,4.1) 68 3.3(2.6,4.2)
10mostfrequentSAEs
Gastroenteritis 10 0.5 11 0.5 17 0.8
Pneumonia 9 0.4 9 0.4 12 0.6
Appendicitis 5 0.2 2 0.1 2 0.1
Bronchitis 2 0.1 5 0.2 2 0.1
Asthma 3 0.1 4 0.2 1 0.0
Asthmaticcrisis 4 0.2 2 0.1 2 0.1
Viralinfection 3 0.1 4 0.2 1 0.0
Febrileconvulsion 1 0.0 4 0.2 2 0.1
Urinarytractinfection 4 0.2 1 0.0 2 0.1
Upperrespiratorytractinfection 2 0.1 2 0.1 2 0.1
AnyrelatedSAE 0 1(gastroenteritis) 0
AnypIMD 1 3 4
Alopeciaareata 1(onsetday67after 1(onsetday81afterdose2) 0
dose2a)
Glomerulonephritis 0 1(onsetday94afterdose2) 1(onsetday4afterdose1)
Acuteglomerulonephritis 0 0 1(onsetday67afterdose2)
ITP 0 1(onsetday268afterdose2) 0
Guillain–Barrésyndrome 0 0 1(onsetday166afterdose2b)
Erythemamultiforme 0 0 1(onsetday347afterdose2c)
Abbreviations:Ad1,A/California/7/2009(H1N1)-AS03vaccineatdose1andsalineplaceboatdose2;Ad2,2dosesofA/California/7/2009(H1N1)-AS03vaccine;AE,
adverseevent;CI,confidenceinterval;ITP,idiopathicthrombocytopenicpurpura;NAd2,2dosesofnonadjuvantedA/California/7/2009(H1N1)vaccine;pIMD,
potentialimmune-mediateddisease;SAE,seriousadverseevent.
aConsideredtobevaccinerelated.
bSubjecthadanunspecifiedinfectioninthemonthbeforeonset.
cDiagnosiswaschangedbytheinvestigatortononspecificviralexanthemaafterunblinding.
ofthestandardHAdose),althoughonlyinthetotalvaccinated wereevaluated,andsubsequenttestingrevealedasubstantialin-
cohort (exploratoryanalysis). cidenceofinfectionwithrespiratorysyncytialvirusandseason-
We observed lower than expected numbers of real-time alinfluenzavirustypesAandB.Potentialeffectsofvariability
PCR–confirmedcasesofA(H1N1)pdm09infection,mostlikely betweencountriesinactivesurveillanceperformanceweremin-
because of limited A(H1N1)pdm09 exposure during 2010, imized by the randomization process. Overall influenza inci-
owing to the absence of the anticipated third pandemic wave dence rates in each group had overlapping 95% CIs, which
during 2010 in the participating countries [14]. Furthermore, doesnot supportthepropositionthatthe adjuvant groups ex-
allstudysubjectsreceivedactiveinfluenzavaccination.Webe- perienced an unqualified general reduction in risk. Neverthe-
lieveouractivesurveillancewasadequate,asmanycasesofILI less, despite the low number of influenza cases, the relative
(cid:129) (cid:129)
554 JID 2014:210 (15August) Nolanetal
VEoftheadjuvantedvaccineafter2doseswashigherthanes- OurresultsprovideevidenceofthepotentialbenefitofAS03-
timatedand wassufficientoverall toreach adefinitiveconclu- adjuvanted pandemic influenza vaccines for control of future
sion.However,thelowcasenumbersledtowideCIsforrelative pandemicswithrespecttopreventionofdiseaseinaparticularly
VE estimates and increased the uncertainty regarding ourex- vulnerableagesegment.Similarly,theavailabilityofeffectivead-
ploration of secondaryend points and subanalyses byage, al- juvanted influenzavaccines for children with reduced antigen
though point estimates for relative VE were the same for contentcouldofferopportunitiesforimprovedcontrolofseason-
subjectsyoungerandthoseolderthan3years. alinfluenza.However,ineithertheseasonalorpandemicsetting,
This study commenced during the 2009–2010 influenza useofAS03-adjuvantedinfluenzavaccinesassociatedwithinjec-
A(H1N1) pandemic in expectation of athird pandemic wave, tion site symptoms, fever,and atheoreticalriskof rarerevents
anditwasnotconsideredethicallyacceptabletoincludeapla- willneedtobebalancedagainsttheriskofdeathorsevereillness
cebogroup.Eventhoughthestudycouldnotprovideabsolute causedbytheseasonalorpandemicinfluenzaviralstrains.
VEvalues,thesecanbeestimatedusingothersourcesfromthe
literature. If an absolute VE of 40% for 2 doses of nonadju-
SupplementaryData
vanted H1N1 vaccine is assumed (from the study by Vesikari
etal[5],againstmainlyinfluenzaA[H3N2]),theestimatedab-
SupplementarymaterialsareavailableatTheJournalofInfectiousDiseases
solute VE for Ad2 in our study is 86%; if an absolute VE for online(http://jid.oxfordjournals.org/).Supplementarymaterialsconsistof
plain H1N1 antigen of 59% is assumed (efficacy estimate dataprovidedbytheauthorthatarepublishedtobenefitthereader.The
from the same influenza A[H1N1] antigen in a quadrivalent postedmaterialsarenotcopyedited.Thecontentsofallsupplementary
dataarethesoleresponsibilityoftheauthors.Questionsormessagesregard-
formulation) [15],the estimated absolute VE for Ad2 is 90%,
ingerrorsshouldbeaddressedtotheauthor.
which is consistent with short-term vaccine effectiveness esti-
mates (86%–100%) reported in case-control studies involving
Notes
children and adults who received 1 dose of H1N1-AS03 [16–
18].Adjuvantbenefitintermsofimmunogenicity,withhigher Acknowledgments. Wethankthefollowingindividuals:inBrazil,Arol-
doCarvahlo,MD,CristianeFinelli,MD,BarbaraFaggin,PhD,Camile
andmorepersistentimmuneresponses,wasalsodemonstrated
Blumer,andstafffromReferenceCentreforSpecialImmunobiologicals;
for 2 H1N1-AS03 doses over 2 nonadjuvanted vaccine doses, inCostaRica,VerónicaUrcuyo,PT,CeliaBarrantes,MD,andtherestof
consistentwithfindingsfrompreviousclinicaltrials[6,19]. contributingstafffromtheInstitutoCostarricensedeInvestigacionesClíni-
cas;inMelbourne,DrPeterHoward,A/ProfessorJodieMcVernon,Marita
Evidence from multiple clinical trials indicatestransient in-
Kefford,RN,EmilyBailey,RN,SharonTrevorrow,RN,JacintaO’Keefe,BSc,
creaseininjectionsitereactionsfollowingAS03-adjuvantedver-
AliceHolloway,andtherestofthecontributingstafffromVIRGo;inSin-
sus nonadjuvanted influenza vaccines, but there has been no gapore,DrAngelaChuaandDrGeorgeChua;inThailand(KhonKaen
evidenceofanincreasedincidenceofmedicallyattendedevents University),DrChanyutSuphakunpinyoandDrPopeKosalaraksa;global
studymanagersKarolienPeetersandLindaEarland;NathalieHouard(GSK
orSAEsassociatedwithAS03use[7].Consistentwiththesestud-
Vaccines),forreal-timePCRanalysis;JanineLindenandStephanieSharp
ies,weobservedhigherratesofinjectionsitepaininH1N1-AS03 (GSKVaccines),forwritingstudyreports;JoanneWolter(independent
recipientsthan in nonadjuvanted vaccine recipients. However,
medicalwriteronbehalfofGSKVaccines),forpreparingthefirstdraftof
themanuscript;andSantoshMysoreandShirinKhalili(XPEPharmaand
grade3painwasreportedfornomorethan3.6%ofchildren.Re-
ScienceonbehalfofGSKVaccines),foreditorialassistanceandmanuscript
portedpotentialimmune-mediateddiseaseswereevenlydistribu- coordination.
tedacrossgroups.Theincidenceofmildfeverincreasedafterthe T. N. contributed to the design, datacollection, and interpretation.
T. N. contributed to the first version of the paper and to all
secondH1N1-AS03dose,asobservedinotherstudiesofthisvac-
revisions.S.R.G.contributedtothestudydesignanddataanalysisand
cineinhealthychildren[20].Therewas noclusteringoffebrile
interpretation.S.R.G.contributedtothecriticalreviewofallversionsof
convulsioncasesintemporalrelationshiptovaccination. the manuscript. M. M., L. W., R. U. G., E. L. P., A. K., M. A. P. S.,
Aftercommencementofourstudy,severalretrospectivestud- A. C. V., S.L.,L.F. S., M. A. R.W., J.C. T., M.H.d. M., I. F., P. K.,
P.Lopez,andC.B.T.wereinvolvedinrecruitment,dataacquisition,and
ies suggested an association between vaccination with another
criticalreviewofallversionsofthemanuscript.A.M.d.L.S.wasinvolved
A(H1N1)pdm09 vaccine (PandemrixTM) and the subsequent inthecriticalreviewofallversionsofthemanuscript.P.Liwasinvolvedin
onsetofnarcolepsyinindividuals<21yearsofageandinadults thestudydesignanddataanalysisandinterpretation.P.Liwasinvolvedin
[21–31].Theseretrospectiveobservationalstudiesaloneareinsuf- thecriticalreviewofallversionsofthemanuscript.S.D.wasinvolvedinthe
interpretation of data and the critical review of all versions of the
ficient to ascribe the risk solely to thevaccine, asother factors manuscript.L.F.,G.D.,andT.B.contributedtothestudydesign,datain-
may playa role. The recent identification of an epitope in the terpretation,andthecriticalreviewofallversionsofthemanuscript.B.I.
andD.W.V.wereinvolvedinthestudydesignanddataanalysisand
H1N1HAproteinthatmimicsanepitopepresentwithinhypo-
interpretation.B.I.andD.W.V.contributedtothecriticalreviewofallver-
cretin [32] suggeststhat exposure of individualswith theHLA
sionsofthemanuscript.T.N.andS.R.G.contributedequallytothis
DQ0602alleletoH1N1can result inanautoimmuneresponse manuscript.
involvingCD4+Tcellsthatcouldleadtotheonsetofnarcolepsy. GlaxoSmithKlineBiologicalswasinvolvedinallstagesofthestudycon-
ductandanalysisandfundedallcostsassociatedwiththedevelopmentand
No narcolepsy cases were reported in thecurrent study, which
thepublishingofthepresentmanuscript.T.N.hadfullaccesstothedata
wastoosmalltodetectrareeventssuchasnarcolepsy. andwasresponsibleforsubmissionofthepublication.
AS03-AdjuvantedInfluenzaA(H1N1)VaccineEfficacy (cid:129) JID 2014:210 (15August) (cid:129) 555
Financial support. This work was supported by GlaxoSmithKline squalene in an oil-in-water emulsion. Expert Rev Vaccines 2012;
Biologicals. 11:349–66.
Potentialconflictsofinterest. Travelassistancewasprovidedtoallin- 8. McElhaneyJE,BeranJ,DevasterJ-M,etal.AS03-adjuvantedversus
vestigatorsbyGlaxoSmithKline(GSK)Biologicalstoparticipateattheinves- non-adjuvantedinactivatedtrivalentinfluenzavaccineagainstseasonal
tigatormeetings.T.N.’sinstitutionhasreceivedresearchgrantsfromGSK, influenzainelderlypeople:aphase3randomisedtrial.LancetInfectDis
Novartis,CSL,Pfizer,andSanofiPasteur.PriortoOct2012,hereceiveda 2013;13:485–96.
smallpaymentforhisroleasamemberoftheindependentdataandsafety 9. KendalA,PereiraM,SkehelJ.Hemagglutinationinhibition.Concepts
monitoringboardforGSKVaccines’humanpapillomavirusvaccine.M.M. andproceduresforlaboratory-basedinfluenzasurveillance.Atlanta,
hasreceivedgrantsandhonorariumfromGSKandhasreceivedtravelfunds Georgia:CentersforDiseaseControlandPreventionandPan-American
forpresentationsfromGSK,MerckSharpandDohme,Novartis,Sanofi HealthOrganization,1985.
Pasteur,andUnitedLaboratories,aswellaspaymentsfordevelopment 10. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R.
of educational presentations from different organizations in the Immunogenicityofamonovalent,aluminum-adjuvantedinfluenza
Philippines.L.W.hasreceivedgrantsfromGSKandhasbeenontheadvi- wholevirusvaccineforpandemicuse.VirusRes2004;103:163–71.
soryboardsforGSK,Merck,andNovartis.Shehasreceivedtravelandac- 11. MorelS,DidierlaurentA,BourguignonP,etal.AdjuvantSystemAS03
commodationallowancesfromGSK,Abbott,andNovartis.R.U.G.served containingα-tocopherolmodulatesinnateimmuneresponseandleads
asaninvitedspeakerforSanofiPasteur,GSK,Wyeth,Pfizer,andMerck.He toimprovedadaptiveimmunity.Vaccine2011;29:2461–73.
hasbeenontheadvisoryboardsforSanofiPasteur,GSK,andWyeth.Hehas 12. HannounC,MegasF,PiercyJ.Immunogenicityandprotectiveefficacy
receivedtravelexpensesfromSanofiPasteur,GSK,Wyeth,andPfizertopar- ofinfluenzavaccination.VirusRes2004;103:133–8.
ticipateinconferencesandmeetings.M.A.P.S.hasreceivedinvestigator 13. BeyerWE,PalacheAM,BaljetM,MasurelN.Antibodyinductionby
andinstitutionalfeesfromGSK.HehasreceivedaconsultancyfeefromNo- influenzavaccinesintheelderly:areviewoftheliterature.Vaccine
vartisandwaspaidforanexperttestimonybyGSK.Hehasservedasamem- 1989;7:385–94.
berofadvisoryboardsforGSK,Novartis,Sanofi,andMerck.Hehasreceived 14. WHO|FluNet-CHARTS.WHO.Availableat:http://www.who.int/
travel grants for presentations from GSK, Novartis, Merck, and Sanofi influenza/gisrs_laboratory/flunet/charts/en/index.html.Accessed21
Pasteur.L.F.S.receivedaninstitutionalgranttoconductthestudy.Hehas June2012.
received travel grants from GSK to present study data at conferences. 15. JainVK,RiveraL,ChandrasekaranV,etal.Efficacyofaninactivated
M.A.R.W.andS.L.havereceivedconsultancyfeesandhonorariafrom quadrivalentinfluenzavaccinecandidateinchildren3-8yearsofage
GSK. M. H. M. has received travel grants to participate at congresses. [abstract1793]. PresentedatIDWeekScientificMeeting;October
P.Lopez’sinstitutionreceivedagrantfromGSKtowardperformingthis 17–21,2012;SanDiego,CA.
study.C.B.T.hasreceivedgrantsfromGSK,Intercell,SanofiPasteur,and 16. VanBuynderPG,DhaliwalJK,VanBuynderJL,etal.Protectiveeffect
NovartisandtravelgrantsfromPediatrica.S.R.G.,P.Li,S.D.,L.F.,G.D., ofsingle-doseadjuvantedpandemicinfluenzavaccineinchildren.In-
T.B.,B.L.I.,andD.W.V.areorwereemployeesoftheGSKgroupof fluenzaOtherRespiViruses2010;4:171–8.
companies.G.D.receivedroyaltiesforpatentsfromWyeth(thelastpayment 17. SkowronskiDM,JanjuaNZ,DeSerresG,etal.EffectivenessofAS03
wasreceivedin2009).S.R.G.,P.Li,L.F.,G.D.,T.B.,B.L.I.,andD.W.V. adjuvantedpandemicH1N1vaccine:case-controlevaluationbasedon
receivedrestrictedshares/stockoptionsoftheGSKgroupofcompanies.L.F. sentinelsurveillancesysteminCanada,autumn2009.BMJ2011;342:
isnowanemployeeofNovavaxandreportsowningNovavaxstock. c7297.
TrademarkStatement. PandemrixisatrademarkoftheGlaxoSmith- 18. MahmudS,HammondG,ElliottL,etal.Effectivenessofthepandemic
Klinegroupofcompanies. H1N1influenzavaccinesagainstlaboratory-confirmedH1N1infec-
AllauthorshavesubmittedtheICMJEFormforDisclosureofPotential tions:population-basedcase-controlstudy.Vaccine2011;29:7975–81.
ConflictsofInterest.Conflictsthattheeditorsconsiderrelevanttothecon- 19. RomanF,VamanT,GerlachB,MarkendorfA,GillardP,DevasterJ-M.
tentofthemanuscripthavebeendisclosed. ImmunogenicityandsafetyinadultsofonedoseofinfluenzaAH1N1v
2009vaccineformulatedwithandwithoutAS03A-adjuvant:preliminary
report of an observer-blind, randomised trial. Vaccine 2010; 28:
References 1740–5.
20. CarmonaA,OmeñacaF,TejedorJC,etal.Immunogenicityandsafety
1. ViboudC,BoëlleP-Y,CauchemezS,etal.Riskfactorsofinfluenza ofAS03-adjuvanted2009influenzaAH1N1vaccineinchildren6–35
transmissioninhouseholds.BrJGenPract2004;54:684–9. months.Vaccine2010;28:5837–44.
2. JanjuaNZ,SkowronskiDM,HottesTS,etal.Transmissiondynamics 21. NohynekH,JokinenJ,PartinenM,etal.AS03adjuvantedAH1N1vac-
andriskfactorsforpandemicH1N1-relatedillness:outbreakinvestiga- cineassociatedwithanabruptincreaseintheincidenceofchildhood
tioninaruralcommunityofBritishColumbia,Canada.Influenza narcolepsyinFinland.PLoSONE2012;7:e33536.
OtherRespiViruses2012;6:e54–62. 22. Miller E, Andrews N, Stellitano L, et al. Risk of narcolepsy in
3. DawoodFS,IulianoAD,ReedC,etal.Estimatedglobalmortality children and young people receiving AS03 adjuvanted pandemic
associated with the first 12 months of 2009 pandemic influenza A/H1N12009influenzavaccine:retrospectiveanalysis.BMJ2013;
AH1N1viruscirculation:amodellingstudy.LancetInfectDis2012; 346:f794.
12:687–95. 23. DauvilliersY,ArnulfI,LecendreuxM,etal.Increasedriskofnarcolepsy
4. JeffersonT,RivettiA,HarndenA,DiPietrantonjC,DemicheliV.Vac- inchildrenandadultsafterpandemicH1N1vaccinationinFrance.
cinesforpreventinginfluenzainhealthychildren.CochraneDatabase Brain2013;136:2486–96.
SystRev2008;CD004879. 24. HeierMS,GautvikKM,WannagE,etal.Incidenceofnarcolepsyin
5. VesikariT,KnufM,WutzlerP,etal.Oil-in-wateremulsionadjuvant NorwegianchildrenandadolescentsaftervaccinationagainstH1N1in-
withinfluenzavaccineinyoungchildren.NEnglJMed2011;365: fluenzaA.SleepMed2013;14:867–71.
1406–16. 25. SzakácsA,DarinN,HallböökT.Increasedchildhoodincidenceofnar-
6. WaddingtonCS,WalkerWT,OeserC,etal.Safetyandimmunogenicity colepsyinwesternSwedenafterH1N1influenzavaccination.Neurology
ofAS03Badjuvantedsplitvirionversusnon-adjuvantedwholevirion 2013;80:1315–21.
H1N1 influenza vaccine in UK children aged 6 months-12 years: 26. WijnansL,LecomteC,deVriesC,etal.Theincidenceofnarcolepsyin
openlabel,randomised,parallelgroup,multicentrestudy.BMJ2010; Europe:before,during,andaftertheinfluenzaA(H1N1)pdm09pan-
340:c2649. demicandvaccinationcampaigns.Vaccine2013;31:1246–54.
7. GarçonN,VaughnDW,DidierlaurentAM.Developmentandeva- 27. Investigationofanincreaseintheincidenceofnarcolepsyinchildren
luationofAS03,anAdjuvantSystemcontainingα-tocopheroland andadolescentsin2009and2010FinalReportofNationalNarcolepsy
(cid:129) (cid:129)
556 JID 2014:210 (15August) Nolanetal
StudySteeringCommittee.2012.Availableat:http://healthupdate.gov. with-Pandemrix-in-children-and-adolescents-and-shows-an-increased-
ie/wp-content/uploads/2012/04/Final_Report_of_National_Narcolepsy_ risk-in-young-adults/.Accessed31July 2013.
Study_Steering_Committee-latest1.pdf.Accessed31July2013. 30. BarkerCIS,SnapeMD.PandemicinfluenzaAH1N1vaccinesandnar-
28. EuropeanCentreforDiseasePreventionandControl.Narcolepsyinas- colepsy:vaccinesafetysurveillanceinaction.LancetInfectDis2013;
sociationwithpandemicinfluenzavaccination.Amulti-countryEuro- 14:227–38.
peanepidemiologicalinvestigation.Stockholm:ECDC;2012September 31. PitkänenM.Increasedriskofnarcolepsyobservedalsoamongadults
ReportNo.Stockholm:ECDC,September2012. vaccinatedwithPandemrixinFinland.2013.Availableat:http://www.
29. Registrystudyconfirmsincreasedriskofnarcolepsyaftervaccination thl.fi/en_US/web/en/pressrelease?id=33516.Accessed31July2013.
withPandemrixinchildrenandadolescentsandshowsanincreased 32. De la Herrán-Arita AK, Kornum BR, Mahlios J, et al. CD4+
riskinyoungadults-MedicalProductsAgency,Sweden.Availableat: T cell autoimmunity to hypocretin/orexin and cross-reactivity to a
http://www.lakemedelsverket.se/english/All-news/NYHETER-2013/ 2009H1N1influenzaAepitopeinnarcolepsy.SciTranslMed2013;
Registry-study-confirms-increased-risk-of-narcolepsy-after-vaccination- 5:216ra176.
AS03-AdjuvantedInfluenzaA(H1N1)VaccineEfficacy (cid:129) JID 2014:210 (15August) (cid:129) 557
